Q4 2021 Bergenbio ASA Earnings Call Transcript
Good morning, and welcome to the BerGenBio Fourth Quarter 2022 -- 2021 report. Today, I will present the highlights and the financials for the fourth quarter of '21. With me today, I also have our CFO, Rune Skeie, and our Chief Scientific Officer, Nigel McCracken, who will be available in the Q&A session.
Just to remind everyone about the formalities. So today's agenda is a short review of the fourth quarter and the recent highlights. The role of AXL, targeting AXL in serious diseases, our strategic priorities, which we describe as three shots on goal. First, the first-line STK11 mutated non-small cell lung cancer opportunity; the second-line relapsed AML opportunity; and the hospitalized COVID-19 opportunity within respiratory infections. We will then go through the finance report and then with the highlights and the outlook.
So in the fourth quarter, we completed the strategic review, and defined what we call three shots on goal for near-term clinical development opportunities of bemcentinib. Firstly, the first-line STK11 mutated opportunity in non
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |